1: Rodvold KA, Gotfried MH, Isaacs RD, O'Donnell JP, Stone E. Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects. Antimicrob Agents Chemother. 2018 Aug 20. pii: AAC.01089-18. doi: 10.1128/AAC.01089-18. [Epub ahead of print] PubMed PMID: 30126953.
2: Iyer R, Moussa SH, Durand-Réville TF, Tommasi R, Miller A. Acinetobacter baumannii OmpA Is a Selective Antibiotic Permeant Porin. ACS Infect Dis. 2018 Mar 9;4(3):373-381. doi: 10.1021/acsinfecdis.7b00168. Epub 2017 Dec 26. PubMed PMID: 29260856.
3: McLeod SM, Shapiro AB, Moussa SH, Johnstone M, McLaughlin RE, de Jonge BLM, Miller AA. Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii. Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01576-17. doi: 10.1128/AAC.01576-17. Print 2018 Feb. PubMed PMID: 29133555; PubMed Central PMCID: PMC5786785.
4: Shapiro AB, Gao N, Jahić H, Carter NM, Chen A, Miller AA. Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514. ACS Infect Dis. 2017 Nov 10;3(11):833-844. doi: 10.1021/acsinfecdis.7b00113. Epub 2017 Aug 28. PubMed PMID: 28835096.
5: Durand-Réville TF, Guler S, Comita-Prevoir J, Chen B, Bifulco N, Huynh H, Lahiri S, Shapiro AB, McLeod SM, Carter NM, Moussa SH, Velez-Vega C, Olivier NB, McLaughlin R, Gao N, Thresher J, Palmer T, Andrews B, Giacobbe RA, Newman JV, Ehmann DE, de Jonge B, O'Donnell J, Mueller JP, Tommasi RA, Miller AA. ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat Microbiol. 2017 Jun 30;2:17104. doi: 10.1038/nmicrobiol.2017.104. PubMed PMID: 28665414.